Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.95 Analyst target: $1.75 Upside: -10.26%
Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.
See the full interactive analysis & chart →Informational only — not investment advice.